Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. - Wikidata - wikimedia - TriplyDB

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

http://www.wikidata.org/entity/Q33299427

about

Toxin-based therapeutic approaches Tumor infiltrating lymphocytes in ovarian cancer Suppression, subversion and escape: the role of regulatory T cells in cancer progression A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors The role of regulatory T cells in cancer.Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions New roads open up for implementing immunotherapy in mesothelioma.SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Immunosuppressive tumor microenvironment in cervical cancer patients Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.Challenges and future perspectives of T cell immunotherapy in cancer A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma.Immunotherapy of malignant brain tumors.Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration Immunotherapy for melanoma: current status and perspectives.Trial watch: Peptide vaccines in cancer therapy Immunogenicity of therapeutic recombinant immunotoxins.Delicate balance among three types of T cells in concurrent regulation of tumor immunity.Construction and Production of Foxp3-Fc (IgG) DNA Vaccine/Fusion Protein Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs.Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection.Immunotherapy opportunities in ovarian cancer.Immunoregulatory T cells: role and potential as a target in malignancy.Immunotoxins: the role of the toxin.

P2860

Q27013664-35F9E7B0-6D38-4475-8318-E58C03A8C1F5 Q27021878-336949AA-2955-4679-95A8-A5DD3976AD68 Q27026151-CE8DAA0B-372A-4F8B-8F9D-F9195D3519A5 Q28731711-72077778-B4BD-4C38-BF46-C0EA371550FD Q33488520-0BD73EFA-A990-4EAF-A1AA-554B8E44B0CA Q33631986-CF865AA8-467B-4169-8E31-5F5C3FDA3E9B Q33907691-994D1FDB-DA0E-43D7-AFF3-97389624C6A0 Q33923717-AF9E02A0-4BCF-463C-9F13-B3A8349DD80A Q33930139-2AC5933F-AA2B-4CAC-814F-ED0B6B55D815 Q34111789-5F1610D9-11FB-4983-9E63-26BF1AF2B956 Q34197717-B66807A0-5F6E-4251-B6F5-044768432B05 Q34331993-87F34AC3-F6E6-44FB-B0FC-536A0044DE02 Q34369526-E266E119-BDC7-4125-8060-9E65D87DA59E Q34880391-4C36AAFC-3EAC-48B0-A39C-F0770542C41D Q34898280-E14D58F9-4315-4614-BD4A-7BC9834FA03C Q35012887-DC4DF3A8-B0CF-41E6-9223-3AF0E246ADB4 Q35033249-F9E1945C-797E-4ABC-8994-0DA77449449E Q35230663-0A13D2C3-65E3-4907-A5FF-1A3C529F780D Q35603131-0806A2C6-8AE7-4585-8314-75D31FA916F6 Q35653164-1686AA05-271F-4691-85FB-FE8698D7EBAE Q35843507-1549F882-4884-4323-9729-E3E37D89DF76 Q35911544-D6C6066E-C507-4A02-8DF9-0498EA5DC262 Q36060244-B8E3621D-172D-4D47-9413-C8F24BC47C21 Q36162929-E8EF3A13-E05E-490E-A6D5-C6006CD8B206 Q36344582-0AF17B86-99BC-4ACB-ABFD-0F4E12736E53 Q36453216-EA528232-197F-4E23-A548-BD8C7DF4AD38 Q36476100-D0DA3C08-58A6-47F9-9955-642027B58F44 Q36593468-554D1E8C-F17F-4941-A17E-7F71424469A7 Q36755513-E04F9B97-EB70-4EEB-A53A-07A5596B4451 Q36828834-A9A6891F-A123-4025-955D-07DC5C8C9EEF Q36853440-38703179-64F7-4344-B307-6592D13D338C Q36952541-367ED23E-DC46-4583-82D2-FF815892631B Q37000445-A2CB2305-69F7-457B-9799-ABB29BD38374 Q37017085-F3839C87-DED6-40FB-A8BC-7D9AF14EEF6E Q37024271-18242F1F-498F-4CB7-83F5-39B82F709B9B Q37055402-1B91780A-D28A-4DB0-AB19-23A6E6E96D89 Q37071100-82247F69-319F-441C-A113-69F1B39AC511 Q37086013-0D29FA2E-8DEF-4E2C-B77F-5B70B0906D76 Q37123810-E5AADEB5-CAC6-4788-AF91-F773302B4BA3 Q37139525-99A926D6-283A-4816-A2A9-C357FA0A9187

P2860

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

http://www.wikidata.org/entity/Q33299427

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@ast

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@en

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@nl

type

label

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@ast

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@en

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@nl

prefLabel

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@ast

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@en

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@nl

P1433

Q33299427-C5C0CF08-20FF-4E8B-8C3B-102908BD55E1

P1476

Q33299427-0C6789C7-934F-45BA-A3F5-5AD154CF7957

P2093

Q33299427-243F1F73-F76F-4EB9-A7EA-B14107A150C9

Q33299427-341E2F0B-A24B-4F85-B0FC-C0D0E8B5C82B

Q33299427-36305F7C-89DC-428E-8A4E-B6E7AE4AF36A

Q33299427-38C5989F-57B1-4030-A47E-08CF7291468E

Q33299427-67BA5822-3E83-42F4-A010-156659864A5A

Q33299427-68FB81C6-0B7C-46AA-A413-5E110F63666F

Q33299427-75B058E7-7ADF-4B18-BD2C-9B25347870E7

Q33299427-A666F8C1-6CC1-4BAA-8181-9065AD885B4F

Q33299427-A7F46FA0-D31A-4A96-BEA7-770A2F0D3267

Q33299427-CED90EE3-6203-471D-8114-55C366998E4E

P2860

Q33299427-121184DD-F280-416D-AE35-7232A61AEEA1

Q33299427-1282652E-FD1B-4D44-A8CF-0E4F6566B79C

Q33299427-2B125647-3476-45F0-BA86-72A82F0DB541

Q33299427-2CED8E77-CAC0-4DFF-89B1-8F03D8C1F7B3

Q33299427-3F67015D-08DC-4F02-8DAF-CD3CFF8038BA

Q33299427-4E6BB54B-5214-484B-B912-AF5EE8EF6089

Q33299427-4FD2F75F-F038-4D12-9D5D-DC5FD89FCF2C

Q33299427-50F916AD-755A-4D92-A5FD-DE84CCCFD457

Q33299427-5160F1DB-7259-4613-B530-EBF01B773F34

Q33299427-581264E2-AC4C-4DE0-9A73-75CAC7C0C387

P304

Q33299427-FC0A22F5-4EF4-4D15-9A6D-0CB2FA917F5F

P31

Q33299427-830F75BD-6C78-4038-BAA9-4B1970C30553

P356

Q33299427-69B1AC54-63A3-4790-A281-C11CCC80FBD7

P407

Q33299427-82EB656E-D4EC-4F63-8CEA-71F00D0DB019

P433

Q33299427-CE5D06B5-459B-4C88-A1F3-7665CE09617F

P478

Q33299427-CCEABA37-E9D5-4782-B3BE-DFB2C5D736D6

P577

Q33299427-5FD81712-9B36-4316-928F-19A0EF778DCE

P5875

Q33299427-824EE824-F586-43F6-B159-D22160FD82A8

P698

Q33299427-4E029DAB-2951-40CD-9FED-8D5DF2E8E108

P932

Q33299427-62130C8A-AEEF-40DA-946F-89BDEBA76B60

P356

JIMMUNOL.179.7.4919

P1433

Journal of Immunology

P1476

Administration of a CD25-direc ...... in regulatory T cells in vivo.

@en

P2093

Aloisio Felipe-Silva

http://www.w3.org/2001/XMLSchema#string

Catherine Levy

http://www.w3.org/2001/XMLSchema#string

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

Donald E White

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Maria J Merino

http://www.w3.org/2001/XMLSchema#string

Mojgan Ahmadzadeh

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

Sharon Mavroukakis

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Cancer immunotherapy: moving beyond current vaccines

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Restoring function in exhausted CD8 T cells during chronic viral infection

Regulatory T cell lineage specification by the forkhead transcription factor foxp3

Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

P304

4919-4928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.179.7.4919

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5965456

http://www.w3.org/2001/XMLSchema#string

P698

17878392

http://www.w3.org/2001/XMLSchema#string

P932

2134981

http://www.w3.org/2001/XMLSchema#string